SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories tops the BSE “HC” space

08 Dec 2011 Evaluate

Ipca Laboratories is currently trading at Rs 262.45, up by 2.75 points or 1.06% from its previous closing of Rs 259.70 on the BSE.

The scrip opened at Rs 259.10 and has touched a high and low of Rs 263.75 and Rs 258.50 respectively. So far 4505 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 351.00 on 14-Jun-2011 and a 52 week low of Rs 230.20 on 04-Oct-2011.

Last one week high and low of the scrip stood at Rs 269.30 and Rs 252.10 respectively. The current market cap of the company is Rs 3264.60 crore.

The promoters holding in the company stood at 46.05% while Institutions and Non-Institutions held 32.06% and 21.89% respectively.

 The other gainers on BSE “HC” space include Piramal Healthcare up by 0.72%, Sun Pharmaceuticals up by 0.66%, Dr Reddys Laboratories up by 0.39%, Cipla up by 0.35% were the opther top gainers amongst BSE “Healthcare” (HC) space.

The company’s net profit for the second quarter of the current fiscal declined by 17.07% at Rs 77.96 crore as compared to Rs 94.01 crore for the corresponding quarter of the last year. The company’s net sales have increased 20.17% at Rs 618.02 crore for the quarter under review as compared to Rs 514.29 crore for the second quarter of the previous year.

Ipca Laboratories Share Price

1543.95 13.35 (0.87%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×